An in-house treatment planning system (TPS) for RSBT was developed, and IC, IC+IS and RSBT treatment plans were simulated for 5 patients with bulky (>40cc) advanced cervical cancer high-risk target volumes (HR-CTVs). All treatment planning was based on magnetic resonance (MR) images with HR-CTV, bladder, rectum, and sigmoid colon contouring done by a radiation oncologist. A bio-and MRI-compatible polycarbonate (Makrolon Rx3158) intrauterine applicator was simulated for IC and RSBT, and the Vienna applicator was simulated for IC+IS BT. 192 Ir was used as the radiation source of IC and IC+IS BT, and the Xoft Axxent TM eBT source was used for RSBT. A 0.5 mm thick tungsten shield was used for RSBT. Two shield models, with azimuthal 45°, zenith 180° (RSBT-45) and azimuthal 180°, zenith 180° (RSBT-180) was selected in this study. BT planning was done by escalating: maximizing HR-CTV dose without exceeding bladder, rectum, and sigmoid dose tolerances. The total dose for each plan included both the external beam radiation therapy (EBRT) and BT doses.
iv 123%, with the average of 113%; the treatment time ratio ranged from 749% to 1188%, with the average of 907%.
Conclusions:
RSBT for advanced cervical cancer can provide variant D90 and treatment time with different azimuthal angles. For RSBT-45, the D90 was improved at the cost of increased treatment time. For RSBT-180, the treatment time was strictly controlled but D90 was not guaranteed. There will be an angle to achieve the balance of More than 90% of cervical cancer is caused by Human papillomavirus (HPV) infection [3, 4] . Not all of the causes of cervical cancer are known, and several other contributing factors include smoking [5] chlamydia infection, stress and stress-related disorders, dietary factors, hormonal contraception, multiple pregnancies, exposure to the hormonal drug diethylstilbestrol, and family history of cervical cancer [6] .
LIST OF TABLES
In 2011, more then 12,000 newly diagnosed cervical cancer cases were reported in the U.S., with the death rate of about 33.8% [7] . The death rate is related to the cancer stage, which is shown in Table 1 . Cervical cancer cases of stage IB2 to stage IV were studied in this work since these advanced-staged cancer cases tend to receive brachytherapy and have bulky volume (>40cc) to benefit from our treatment method. Larger early stage tumors (IB2 and IIA more than 4 cm) may be treated with radiation therapy and cisplatin-based chemotherapy, hysterectomy (which then usually requires adjuvant radiation therapy), or cisplatin chemotherapy followed by hysterectomy
Advanced stage tumors (IIB-IVA) are treated with radiation therapy and cisplatinbased chemotherapy [1].
Brachytherapy
Brachytherapy (BT) plays a crucial role in the treatment of invasive cervical cancer from stage I to IV, especially in advanced stage (IB2 or higher) [8, 9] . It is an intracavitary (IC) high-dose-rate (HDR) radiation therapy, delivering much higher dose per fraction than external beam radiotherapy (EBRT) to the target tumor volume without violating the organs at risk (OAR) toxicity threshold because of the very high dose gradient around the source (about 10% per mm) [9] . Conventionally, a radiation source with a radially symmetric dose distribution is used in brachytherapy. As a result, the OAR around the cervical cancer, such as bladder, sigmoid and rectum restrict the radiation dose that can be delivered to the non-symmetric extensions of bulky (>4 cm)
tumors [10] . To compensate for the sometimes poor conformance of the intracavitaryonly dose distribution, needle-based intracavitary plus interstitial (IC+IS) BT is can be used [8] [9] [10] [11] [12] [13] [14] . 
Rotating-shield brachytherapy
Rotating shield brachytherapy (RSBT) was conceptually proposed by Ebert in
2002 [16] . It delivered the dose through a partially shielded radiation source in an optimized step-shot fashion to improve tumor dose conformity. It's a type of intensitymodulated brachytherapy (IMBT) in which the amount of time the shield is pointed in a given direction is controlled. RSBT may be less invasive than interstitial BT since there is no need of needles, and the extra time for setting up interstitial applicator is spared.
With the electronic radiation source which is with relatively low energy (26 keV on average), RSBT enables clinical staff to be in the treatment room during delivery, and would eliminate the need for an expensive shielded room for conventional BT. Thus patients could be treated in a room next to the MRI or CT room, reducing the added complexity of transporting patients between the BT suite and the imaging room. Other groups have studied the theoretical effectiveness of RSBT for prostate [17] and breast [18] cancer.
Rationale of our study
In this work, we proposed to apply RSBT with electronic source for cervical cancer with bulky (>40cc) volume. With the relatively low source energy (average 26ev),
we could use 2mm-thick tungsten shield which can be placed into the IC BT applicator.
We also developed a treatment planning system for RSBT to compare the treatment result with conventional IC and IC+IS BT.
Commercially available HDR-BT planning systems of which we are aware are capable of IC+IS BT. The cervical cancer cases, materials, and the dose optimization and calculation mechanism will be discussed in the following sections. One BT plan was assumed to be repeated during subsequent BT fractions. The MRI images were acquired from the first fraction. The linear-quadratic parameters used were: α/β = 3 Gy for OAR and α/β = 10 Gy for tumor [19] . The final dose result was the summation of EBRT and dose/fraction multiplied by fraction number in BT. We used the OAR dose constraints of D2cc ≤ 75 Gy 3 for rectum and sigmoid, D2cc ≤ 90 Gy 3 for bladder, which is consistent with that used by other groups [9, 20] .
Patients and dose prescriptions

Radiation Source and applicator
For RSBT, we simulated the same applicator as that in intracavitary BT as shown in figure 1-1. We proposed an electronic radiation source, Xoft Axxent TM for RSBT, since with the relatively low energy (26.8 keV), only 0.5 mm thick tungsten shield is needed to reduce the transmission to less than 0.1%. According to Ebert's study [16] , the more transmission, the poorer dose conformity can be achieved. In our study, we assumed the shield was rotated along the curved axis of the applicator.
There are two other reason why we selected the Xoft Axxent TM (Xoft Inc., Sunnyvale, CA) miniature x-ray (photon) tube as the radiation source for RSBT. First, its dose rate in water at 2 cm lateral to the source axis is greater than 1 Gy/min, which is comparable to that of 192 Ir BT, preventing a significant treatment time increase for RS-IMBT. Second, the transmission of the low energy (26.8 keV average) photons emitted by the eBT source can be reduced to 0.1% with only 0.5mm of tungsten shield. Over 2 cm of gold or tungsten would be required to achieve a similar shield transmission for 192 Ir photons, which is too much to fit inside an intracavitary uterine applicator. 
Delivery technique
Figure 2-7. RSBT coordinate system for dose calculation and shield rotating&moving. The eBT source is placed in the applicator positions sequentially. The dashed pyramid indicates the azimuthal and zenith shield emission angles. Every point in the space is defined in two coordinate systems: the laboratory and source coordinate system. The shield is rotated along z' k . The dwell time of each position is optimized using a linear least square optimization technique. After a full rotation at one dwell position, the source moves to the next one and the process is repeated.
As shown in figure 2-7, the radiation source was simulated to be placed at the dwell positions sequentially within the applicator. At each dwell position, the radiation source was rotated around z' k . The number of emission per dwell position can be specified by the user. The emission time was optimized with a linear least square optimizer such that the dose distribution would conform to the tumor shape. The source moved to the next dwell position and repeated this process after a 360° rotation. We also used different shield zenith angle, Δθ, from 90° to 180°. RSBT source with shield rotating and shifting process (a) the shield azimuth angle is equal to the rotation step angle, so that there isn't overlap between each rotation, (b) The shield azimuth angle is greater than the rotation step angle, which brings overlap between each rotation, (c) The minimal zenith angle is shown such that there won't be any cold points outside the applicator, (d) The zenith angle is larger so there will be overlap between dwell positions.
Two azimuthal angle shields (45° and 180°) with constant zenith angle (180°)
were applied to all the 5 patients. They are called RSBT-45 and RSBT-180. These two angles were selected to represent fine and broad azimuthal shield angles, and are not expected to be optimal choices. More shield model with different azimuthal and zenith angle was applied only to patient 1, to investigate the effect of azimuthal and zenith angle.
Dose calculation
The TG-43 method was used for dose calculation, and the medium through which the photons transmitted was assumed to be water.
The definition of each function in equation 1 and the corresponding approximated functions are shown in table 2. 
Geometry function of mass density and the distance from the radiation source. In this study the medium intensity is assumed to be 1g/ cm 3 and
, we used the TG-43 formalism in this paper 
Optimization methods
With the prescription dose specified by user, which in this study is 27.5 Gy, a least-squares optimization method was used to determine the emission times at each emission of all the dwell positions. The emission times were then uniformly scaled as high as possible such that none of the rectum, bladder, or sigmoid GEC-ESTRO recommended D 2cc values was exceeded. The objective and update function is shown in Equation 2 and 3. [21] . Optimization update equation Table 2 
T k
The number of voxels of the kth organ β
The penalty factor for different situations
The prescription dose on tumor surface
The dose greater than prescription in the ith voxel, kth organ
The dose less than prescription in the ith voxel, kth organ
The overdose threshold for dose-volume parameter
The underdose threshold for dose-volume parameter
The dose delivered to the ith voxel, by source at jth emission
Evaluation metric
With the MRI-guided TPS, the tumor volume uncertainty was reduced [20, 22] thus a higher structure related parameter, the minimal dose value for the hottest 90% 
DVH curve
The DVH for all the 5 patients are shown in figure 3-2. 
Effect of azimuthal angle
We applied a series shield with different azimuthal angle for patient 1 RSBT treatment. The treatment time is basically inverse linearly dependent on the azimuthal angle. There is one optimal azimuthal angle to achieve the best D90. The time-D90 curve is shown in figure 3-4 . 
CHAPTER 4 DISCUNSSION AND CONCLUSION
The treatment outcome, in terms of D90, of RS-BT is always better than intracavitary BT, which is shown in the DVH curves. The advantage of RSBT over interstitial BT is highly dependent on the tumor shape and azimuthal angle selected.
We can group patient 1 and 2 together since the D90 of RSBT with 180° azimuthal angle is at least similar to that of interstitial BT. The RSBT in these two cases will provide less invasiveness and cost acceptable extra treatment time which is less than 5 min/fraction. For patients 3,4, and 5, the RSBT-180 is less effective than IC+IS since it lowers the D90 below that of interstitial BT. We can see from figure 3-1 that the 45°
RSBT will always get the best treatment outcome, the highest D90 but the extra treatment time will be very large in terms of more than 30 min/fraction.
So, for some cervical cancer shapes, RSBT with 180° azimuthal angle is a good alternative for interstitial BT, such as patient 1 and 2. However, for other irregular shapes, RSBT with finer angle such as 45° could be considered but much more treatment time is required.
The dose calculation model in our study is an approximation. We are currently using a point source model, without considering the shield transmission (<0.1%) and photon scattering. It is reasonable to assume that the dosimetric results of our study are upper bounds of the treatment outcomes of RSBT, since all these neglected factors will only cause irregular dose distribution thus decrease the D90 result.
Another problem is the escalated dose result is one BT fraction × 5. In real clinical treatment, the tumor and OAR locations and size change with time, especially for HR-CTV. An MRI scan is thus required just prior to RSBT delivery in order to ensure organ structures of the proper sizes and extends are used for planning.
In our simulation study, the result shows RSBT could provide higher D90 than conventional IC+IS BT. More experimental work will be needed in the future to verify our computational results. Moreover, our results show that the parameter selection for RSBT is very important for different tumor shapes. An algorithm that automatically searches the best set of parameters will be helpful for making the treatment plan. (3 out of 5 is better with 45, not 60% of all patients) (tg43 method is not specific for shield)
